Days af­ter Mer­ck deal, Sutro rolls out $85M E round to fund in­ter­nal can­cer pipeline

Just days af­ter an­nounc­ing a deal with Mer­ck, South San Fran­cis­co’s Sutro Bio­Phar­ma is trot­ting out a siz­able in­fu­sion of cash to­day to fu­el its own in­ter­nal pipeline of can­cer drugs.

The com­pa­ny says it’s raised $85.4 mil­lion from a rather lengthy list of in­vestors to push two ear­ly-stage pro­grams through the clin­ic. Sutro, though, is prob­a­bly bet­ter known for its man­u­fac­tur­ing tech, which al­lows them to pro­duce ther­a­peu­tic pro­teins with­out us­ing live cells as minia­ture fac­to­ries. That’s par­tic­u­lar­ly use­ful for speed­ing up dis­cov­ery and de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.